Abstract:Background: Myocardial injury is a common heart disease that involves various forms of cell death, including pyroptosis. Lipopolysaccharide (LPS) can simulate the inflammatory response of cardiomyocytes, resulting in their damage. Sirtuin 3 (SIRT3), a mitochondrial deacetylase, has been shown to play a role in cardiac protection. This study aimed to investigate whether SIRT3 mitigates inflammation-induced cardiomyocyte pyroptosis and alleviates LPS-induced myocardial injury via the mitochondrial ubiquitin ligase (MITOL)-dependent mechanism. Methods: Mouse and H9C2 cardiomyocyte models were used to simulate myocardial inflammatory injury by LPS treatment. Cardiac ultrasound, protein expression analysis, mRNA expression detection, and serum biochemical indicators were used to assess the extent of myocardial injury. The EdU experiment was conducted to detect cell proliferation capacity. DCFH-DA fluorescence was used to measure Reactive Oxygen Species (ROS) levels. JC-1 probe analysis was used to assess the aggregate/monomer ratio in different treatment groups. Furthermore, SIRT3 treatment and MITOL silencing experiments were conducted to explore the impact of SIRT3 on cardiomyocyte pyroptosis and whether it functions through MITOL. Scanning electron microscopy experiments were conducted to assess the reversal of the protective effect of SIRT3 by silencing MITOL. Results: The experimental results showed that LPS treatment significantly impaired mouse cardiac function, increased the expression of pyroptosis-related proteins in cardiomyocytes, elevated serum myocardial injury indicators, and increased the mRNA expression of inflammatory factors (tumor necrosis factor-alpha (TNFα) and interleukin-1β (IL-1β)). SIRT3 treatment significantly reduced LPS-induced myocardial injury, improved cardiac function, reduced the expression of pyroptosis-related proteins, and decreased inflammatory factors. Silencing MITOL reversed the protective effect of SIRT3 on cardiomyocyte injury, suggesting that SIRT3 exerted its therapeutic effect through MITOL. Conclusion: This study revealed that SIRT3 mitigated inflammation-induced cardiomyocyte pyroptosis via a MITOL-dependent mechanism, thereby alleviating LPS-induced myocardial injury. This finding provides a new molecular target for the treatment of myocardial inflammation-related diseases and lays a theoretical foundation for the development of cardiac protection strategies. Future research can further explore the potential application of the SIRT3-MITOL axis in cardiac diseases, providing effective treatment methods for cardiac patients.

SirT3 Activates AMPK-related Mitochondrial Biogenesis and Ameliorates Sepsis-Induced Myocardial Injury

Sirt3 is a Novel Target to Treat Sepsis Induced Myocardial Dysfunction by Acetylated Modulation of Critical Enzymes Within Cardiac Tricarboxylic Acid Cycle

SIRT3-mediated mitochondrial autophagy in refeeding syndrome-related myocardial injury in sepsis rats

ANXA1sp modulates the protective effect of Sirt3‐induced mitophagy against sepsis‐induced myocardial injury in mice

SIRT1/3 Activation by Resveratrol Attenuates Acute Kidney Injury in a Septic Rat Model

BMAL1 alleviates myocardial damage in sepsis by activating SIRT1 signaling and promoting mitochondrial autophagy

Mitochondrial aldehyde dehydrogenase activity protects against lipopolysaccharide‑induced cardiac dysfunction in rats.

Novel Mechanism of SIRT3 Regulation in Cardiac Inflammatory Injury: The Key Role of MITOL

Abstract 15090: AMP-Activated Protein Kinase Upregulates Sodium-Dependent Glucose Transporter SGLT1, Which Contributes to Cardiac Ischemia-Reperfusion Injury

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

Sirt3 ameliorates mitochondrial dysfunction and oxidative stress through regulating mitochondrial biogenesis and dynamics in cardiomyoblast.

Inhibition of aerobic glycolysis alleviates sepsis‐induced acute kidney injury by promoting lactate/Sirtuin 3/AMPK‐regulated autophagy

Sirt3 mitigates LPS‐induced mitochondrial damage in renal tubular epithelial cells by deacetylating YME1L1

PTX3 mediates PI3K/AKT/mTOR signaling to downregulate apoptosis and autophagy to attenuate myocardial injury in sepsis

Resveratrol Protects the Myocardium in Sepsis by Activating the Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway and Inhibiting the Nuclear Factor-κB (NF-κB) Signaling Pathway

AMPKα2 Overexpression Reduces Cardiomyocyte Ischemia-Reperfusion Injury Through Normalization of Mitochondrial Dynamics

Regulation of Sirtuins in Sepsis-Induced Myocardial Damage: The Underlying Mechanisms for Cardioprotection

Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway

Activation of sigma-1 receptor ameliorates sepsis-induced myocardial injury by mediating the Nrf2/HO1 signaling pathway to attenuate mitochondrial oxidative stress

IL-13 Derived Type 2 Innate Lymphocytes Ameliorates Cardiomyocyte Apoptosis Through STAT3 Signaling Pathway

Endogenous β3-adrenergic receptor activation alleviates sepsis-induced cardiomyocyte apoptosis via PI3K/Akt signaling pathway